Relmada Therapeutics to Report First Quarter 2026 Financial Results on Tuesday, May 12, 2026

CORAL GABLES, Fla., May 06, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced plans to host a conference call and webcast on Tuesday, May 12, 2026 at 4:30 PM ET to discuss financial results for the first quarter ended March 31, 2026, and recent business progress.